Efgartigimod

Generic Name: Efgartigimod

Clinical Trials

Efgartigimod for the Treatment of Guillain-Barré Syndrome

Phase 2

Not yet recruiting

Conditions: Guillain-Barre Syndrome (GBS)

Interventions: Drug: efgartigimod

First Posted Date: 2025-03-20

Last Posted Date: 2025-03-20

Lead Sponsor: Zhongming Qiu

Target Recruit Count: 20

Registration Number: NCT06885762

Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod

Phase 4

Not yet recruiting

Conditions: Myasthenia Gravis Crisis
Myasthenia Gravis Exacerbations
AChR Myasthenia Gravis

Interventions: Drug: Efgartigimod

First Posted Date: 2025-03-06

Last Posted Date: 2025-03-06

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 20

Registration Number: NCT06860633

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States

A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Phase 2

Not yet recruiting

Conditions: Immune-mediated Thrombotic Thrombocytopenic Purpura

Interventions: Drug: efgartigimod

First Posted Date: 2025-02-17

Last Posted Date: 2025-02-17

Lead Sponsor: University of Minnesota

Target Recruit Count: 15

Registration Number: NCT06831058

Seronegative Myasthenia Gravis - Efgartigimod IV

Phase 3

Recruiting

Conditions: Efgartigimod
Generalized Myasthenia Gravis

Interventions: Biological: efgartigimod

First Posted Date: 2024-09-09

Last Posted Date: 2024-09-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 30

Registration Number: NCT06587867

Locations: 🇨🇦
University Health Network, Division of Neurology, Toronto General Hospital, Toronto, Ontario, Canada

Efgartigimod for Stiff Person Syndrome (ESPS)

Phase 2

Not yet recruiting

Conditions: Stiff-Person Syndrome

Interventions: Biological: Efgartigimod

First Posted Date: 2024-07-30

Last Posted Date: 2025-04-11

Lead Sponsor: University of South Florida

Target Recruit Count: 10

Registration Number: NCT06528392

Locations: 🇺🇸
University of South Florida, Carol and Frank Morsani Center for Advanced Healthcare, Tampa, Florida, United States

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/or Breastfeeding.

Recruiting

Conditions: Myasthenia Gravis
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

Interventions: Biological: Efgartigimod

First Posted Date: 2024-03-08

Last Posted Date: 2025-02-28

Lead Sponsor: argenx

Target Recruit Count: 279

Registration Number: NCT06299748

Locations: 🇺🇸
United BioSource LLC, Morgantown, West Virginia, United States

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Recruiting

Conditions: Myasthenia Gravis

Interventions: Biological: efgartigimod

First Posted Date: 2024-03-07

Last Posted Date: 2025-04-01

Lead Sponsor: argenx

Target Recruit Count: 680

Registration Number: NCT06298565

Locations: 🇺🇸
SFM Clinical Research, LLC, Boca Raton, Florida, United States
🇺🇸
Norton Neuroscience Institute, Louisville, Kentucky, United States
🇺🇸
National Neuromuscular Research Institute, Austin, Texas, United States

and more 3 locations

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

Phase 2

Completed

Conditions: Primary Sjögren's Syndrome

Interventions: Biological: Efgartigimod

First Posted Date: 2024-01-12

Last Posted Date: 2025-04-03

Lead Sponsor: argenx

Target Recruit Count: 24

Registration Number: NCT06203457

Locations: 🇭🇺
Debreceni Egyetem, Debrecen, Hungary
🇵🇱
Centrum Medyczne Pratia Poznan, Skorzewo, Poland
🇵🇱
FutureMeds sp zoo, Wroclaw, Poland

and more 8 locations

Open Label Extension of Efgartigimod in Adults with Post-COVID-19 POTS

Phase 2

Terminated

Conditions: Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome

Interventions: Drug: Efgartigimod

First Posted Date: 2023-06-26

Last Posted Date: 2024-12-04

Lead Sponsor: argenx

Target Recruit Count: 33

Registration Number: NCT05918978

Locations: 🇺🇸
North Shore University HealthSystem, Glenview, Illinois, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 6 locations

Efficacy and Safety Study of Efgartigimod in Adults with Post-COVID-19 POTS

Phase 2

Completed

Conditions: Postural Orthostatic Tachycardia Syndrome

Interventions: Drug: Placebo
Drug: Efgartigimod

First Posted Date: 2022-12-01

Last Posted Date: 2024-10-03

Lead Sponsor: argenx

Target Recruit Count: 53

Registration Number: NCT05633407

Locations: 🇺🇸
University of California, San Diego Sulpizio Cardiovascular Center, La Jolla, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Stanford Movement Disorder Center, Palo Alto, California, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy